Clinical trial
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated…
NCT00038870 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00038870 |
|---|---|
| Title | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes |
| Official title | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Immunex Corporation Industry National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia |
| Intervention type | Biological |
| Interventions | Dendritic Cell Activated Lymphocyte |
| Enrollment | 0 |
| Start date | Jan 31, 2001 |
| Primary completion | Jan 14, 2003 |
| Completion | Jan 14, 2003 |
| First posted | Jun 7, 2002 |
| Last update posted | Oct 25, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: